Pulmatrix (PULM) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
26 Oct, 2026Opening remarks and agenda
Special meeting held in lieu of the annual meeting; Peter Ludlum served as chair and secretary, then turned meeting conduct over to consultant Jordan Medalia.
Record date was August 28, 2026; polls opened for eight matters, with formal business followed by an operations update and voting results.
Specific resolutions to be voted on
Approve issuance of common shares representing more than 20% of pre-merger shares to Eos SENOLYTIX stockholders and the merger-related change of control under Nasdaq rules 5635(a) and (b).
Approve a reverse split at a board- and Eos-agreed ratio of 1-for-2 to 1-for-10, or any ratio in between; increase authorized common shares from 200 million to 250 million.
Ratify CBIZ CPAs P.C. for FY ended December 31, 2026; if the merger closes, Stephano Slack LLC is expected to serve as independent auditor.
Elect Michael J. Higgins and Anand Varadan as Class III directors through the 2029 annual meeting; approve advisory executive compensation and vote frequency, plus the Eos Incentive Plan.
Board and executive committee updates
Peter Ludlum was identified as Interim CEO and Interim CFO; directors introduced were Michael J. Higgins, Richard Batycky, Christopher Cabell, Anand Varadan and Todd Bazemore.
Higgins and Varadan were nominated for Class III terms through the 2029 annual meeting; if the merger closes, the board will be reconstituted under the merger agreement.
Latest events from Pulmatrix
- Special meeting delayed; merger, capital structure and governance proposals remain on the ballot.PULM
Proxy filing - Resale of up to 491,607 shares brings dilution risk but no proceeds to the registrant.PULM
Registration filing - Pulmatrix and Eos SENOLYTIX merge, creating a controlled company with Eos holding 94%.PULM
Proxy filing - Future hinges on the Eos merger, with cash runway limited and all clinical work paused.PULM
Q2 2026 - Registering 490,910 shares for resale may dilute current holders by up to 13%.PULM
Registration filing - Registering 490,910 shares for resale may dilute current holders by 13%, with no proceeds to the company.PULM
Registration filing - Merger with Eos SENOLYTIX is critical as Q1 net loss narrows and cash reserves remain limited.PULM
Q1 2026 - Revenue fell to nil in 2025 as the company pivots to merger and asset monetization strategies.PULM
Q4 2025 - Cullgen and Pulmatrix merge to form a Nasdaq-listed biotech with $65M cash and advanced pipeline.PULM
M&A Announcement